JP6918829B2 - 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害 - Google Patents

血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害 Download PDF

Info

Publication number
JP6918829B2
JP6918829B2 JP2018554659A JP2018554659A JP6918829B2 JP 6918829 B2 JP6918829 B2 JP 6918829B2 JP 2018554659 A JP2018554659 A JP 2018554659A JP 2018554659 A JP2018554659 A JP 2018554659A JP 6918829 B2 JP6918829 B2 JP 6918829B2
Authority
JP
Japan
Prior art keywords
compound
liposome
atr
liposomes
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018554659A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505584A (ja
Inventor
ダリル・シー・ドラモンド
ボリン・ゲン
ドミトリ・ビー・カーポティン
サレシュ・ケー・ティッパラジュ
アレキサンダー・コシュカーイェフ
オザン・アルカン
Original Assignee
メリマック ファーマシューティカルズ インコーポレーティッド
メリマック ファーマシューティカルズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メリマック ファーマシューティカルズ インコーポレーティッド, メリマック ファーマシューティカルズ インコーポレーティッド filed Critical メリマック ファーマシューティカルズ インコーポレーティッド
Publication of JP2019505584A publication Critical patent/JP2019505584A/ja
Priority to JP2021120731A priority Critical patent/JP7439023B2/ja
Application granted granted Critical
Publication of JP6918829B2 publication Critical patent/JP6918829B2/ja
Priority to JP2023196825A priority patent/JP2024023349A/ja
Priority to JP2025282870A priority patent/JP2026053650A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018554659A 2016-01-11 2017-01-11 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害 Active JP6918829B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021120731A JP7439023B2 (ja) 2016-01-11 2021-07-21 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2023196825A JP2024023349A (ja) 2016-01-11 2023-11-20 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2025282870A JP2026053650A (ja) 2016-01-11 2025-12-25 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662277262P 2016-01-11 2016-01-11
US62/277,262 2016-01-11
US201662420258P 2016-11-10 2016-11-10
US62/420,258 2016-11-10
US201762444172P 2017-01-09 2017-01-09
US62/444,172 2017-01-09
PCT/US2017/012939 WO2017123588A1 (en) 2016-01-11 2017-01-11 Inhibiting ataxia telangiectasia and rad3-related protein (atr)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021120731A Division JP7439023B2 (ja) 2016-01-11 2021-07-21 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Publications (2)

Publication Number Publication Date
JP2019505584A JP2019505584A (ja) 2019-02-28
JP6918829B2 true JP6918829B2 (ja) 2021-08-11

Family

ID=59311885

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018554659A Active JP6918829B2 (ja) 2016-01-11 2017-01-11 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2021120731A Active JP7439023B2 (ja) 2016-01-11 2021-07-21 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2023196825A Pending JP2024023349A (ja) 2016-01-11 2023-11-20 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2025282870A Pending JP2026053650A (ja) 2016-01-11 2025-12-25 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021120731A Active JP7439023B2 (ja) 2016-01-11 2021-07-21 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2023196825A Pending JP2024023349A (ja) 2016-01-11 2023-11-20 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2025282870A Pending JP2026053650A (ja) 2016-01-11 2025-12-25 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Country Status (17)

Country Link
US (5) US10570119B2 (cg-RX-API-DMAC7.html)
EP (3) EP3936153B1 (cg-RX-API-DMAC7.html)
JP (4) JP6918829B2 (cg-RX-API-DMAC7.html)
KR (2) KR102461219B1 (cg-RX-API-DMAC7.html)
CN (2) CN116211803B (cg-RX-API-DMAC7.html)
AU (3) AU2017207299B2 (cg-RX-API-DMAC7.html)
DK (2) DK3402532T3 (cg-RX-API-DMAC7.html)
ES (2) ES2997263T3 (cg-RX-API-DMAC7.html)
FI (1) FI3936153T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241512T1 (cg-RX-API-DMAC7.html)
IL (2) IL260487B2 (cg-RX-API-DMAC7.html)
MA (1) MA43870A (cg-RX-API-DMAC7.html)
MX (1) MX2018008507A (cg-RX-API-DMAC7.html)
PL (1) PL3402532T3 (cg-RX-API-DMAC7.html)
PT (1) PT3936153T (cg-RX-API-DMAC7.html)
SI (1) SI3936153T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017123588A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021176879A (ja) * 2016-01-11 2021-11-11 メリマック ファーマシューティカルズ インコーポレーティッド 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI755629B (zh) * 2018-09-13 2022-02-21 台灣微脂體股份有限公司 含鎮靜藥物之緩釋藥物組合物及其用途
EP3866764A4 (en) * 2018-10-17 2022-07-13 Taiwan Liposome Company, Ltd. DELAYED RELEASE PHARMACEUTICAL COMPOSITIONS WITH AN IMMUNOMODULATING AGENT AND USES THEREOF
US20230190752A1 (en) * 2020-05-07 2023-06-22 Washington University Compositions and methods for predicting therapeutic outcome
AU2021292747A1 (en) 2020-06-18 2023-02-23 Akagera Medicines, Inc. Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
EP4210692A4 (en) * 2020-09-14 2024-10-02 Zhuhai Beihai Biotech Co., Ltd. Formulations of cabazitaxel
AU2021360636A1 (en) 2020-10-16 2023-06-15 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
WO2025019346A2 (en) * 2023-07-14 2025-01-23 Celator Pharmaceuticals, Inc. Methods of use of a liposomal composition comprising an atr inhibitor
WO2025019344A2 (en) * 2023-07-14 2025-01-23 Jazz Pharmaceuticals, Inc. Combinations comprising an atr inhibitor and a parp inhibitor and methods of use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990610A (en) 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
DE602004015429D1 (de) 2003-03-11 2008-09-11 Pfizer Prod Inc Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
GB0411401D0 (en) 2004-05-21 2004-06-23 Tissuomics Ltd Penetrating radiation measurements
EP1778648A2 (en) 2004-08-19 2007-05-02 ICOS Corporation Compounds useful for inhibiting chk1
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
MX2009002422A (es) 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
EP2153820A4 (en) 2007-05-14 2013-12-25 Konica Minolta Holdings Inc LIPOSOM AND METHOD FOR THE PRODUCTION OF LIPOSOMY
KR101712576B1 (ko) 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
JP5951994B2 (ja) 2008-12-19 2016-07-13 イマージョン コーポレーションImmersion Corporation 対話型ペインティングゲーム及び関連するコントローラ
TW201028410A (en) * 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
BR112012005343A2 (pt) 2009-09-10 2016-03-22 Novartis Ag sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼ阻害剤として有用な化合物
JP2013526538A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143423A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
JP2013529643A (ja) 2010-06-23 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用なピロロピラジン誘導体
CN102485213A (zh) * 2010-12-01 2012-06-06 沈阳药科大学 伊立替康脂质体及其制备方法
CN102485212B (zh) * 2010-12-01 2014-04-09 沈阳药科大学 苹果酸舒尼替尼脂质体及其制备方法
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014KN00943A (cg-RX-API-DMAC7.html) * 2011-09-30 2015-08-21 Vertex Pharma
RU2018147217A (ru) 2011-09-30 2019-01-18 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) * 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) * 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US8912198B2 (en) * 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
EP3164420A4 (en) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
EP3936153B1 (en) 2016-01-11 2024-08-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021176879A (ja) * 2016-01-11 2021-11-11 メリマック ファーマシューティカルズ インコーポレーティッド 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP7439023B2 (ja) 2016-01-11 2024-02-27 メリマック ファーマシューティカルズ インコーポレーティッド 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害

Also Published As

Publication number Publication date
IL313681B1 (en) 2026-08-01
AU2023282309B2 (en) 2025-09-18
JP7439023B2 (ja) 2024-02-27
IL260487B2 (en) 2024-11-01
JP2021176879A (ja) 2021-11-11
CN108697811A (zh) 2018-10-23
US11787781B2 (en) 2023-10-17
US11028076B2 (en) 2021-06-08
ES2997263T3 (en) 2025-02-14
US20190135789A1 (en) 2019-05-09
EP4438127A2 (en) 2024-10-02
CN108697811B (zh) 2023-04-07
JP2024023349A (ja) 2024-02-21
KR20180096787A (ko) 2018-08-29
JP2019505584A (ja) 2019-02-28
EP3936153A1 (en) 2022-01-12
IL260487B1 (en) 2024-07-01
EP3936153B1 (en) 2024-08-21
JP2026053650A (ja) 2026-03-25
PL3402532T3 (pl) 2022-08-22
EP4438127A3 (en) 2024-12-25
SI3936153T1 (sl) 2025-03-31
CN116211803A (zh) 2023-06-06
HRP20241512T1 (hr) 2025-01-03
PT3936153T (pt) 2024-11-25
MA43870A (fr) 2021-05-26
DK3402532T3 (da) 2022-07-11
FI3936153T3 (fi) 2024-11-21
KR20230002511A (ko) 2023-01-05
MX2018008507A (es) 2019-07-04
WO2017123588A1 (en) 2017-07-20
US20210300905A1 (en) 2021-09-30
ES2921008T3 (es) 2022-08-16
AU2025279601A1 (en) 2026-01-15
IL313681A (en) 2024-08-01
DK3936153T3 (da) 2024-11-25
AU2023282309A1 (en) 2024-01-18
EP3402532A4 (en) 2019-09-11
AU2017207299B2 (en) 2023-09-21
US10570119B2 (en) 2020-02-25
KR102461219B1 (ko) 2022-10-31
EP3402532B1 (en) 2022-04-13
AU2017207299A1 (en) 2018-08-02
CN116211803B (zh) 2024-10-11
US20200399247A1 (en) 2020-12-24
IL260487A (cg-RX-API-DMAC7.html) 2018-09-20
KR102558501B1 (ko) 2023-07-21
EP3402532A1 (en) 2018-11-21
US20250333396A1 (en) 2025-10-30
US20230416236A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
JP7439023B2 (ja) 血管拡張性失調症及びRad3関連タンパク質(ATR)の阻害
JP2018524382A (ja) キラルジアリール大環状分子及びその使用
TW201725039A (zh) 穩定之喜樹鹼醫藥組合物
WO2019073296A1 (en) LIPOSOMAL FORMULATIONS OF BISANTRENE OR DERIVATIVES OR THE LIKE THEREOF
KR20090031744A (ko) 항암제 내성 극복제
US20190262453A1 (en) Design and composition of cell-stabilized pharmaceutical formulations
CN121646480A (zh) 治疗p53基因突变或缺陷阴性癌症、肿瘤患者
CN121985960A (zh) 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者
CN121969391A (zh) 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症
HK40065701B (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
HK40065701A (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
EP4357340A1 (en) Salt of selective fgfr4 inhibitor, and preparation method therefor and application thereof
EA039513B1 (ru) Ингибитор атаксии-телеангиэкстазии и rad3-родственного белка (atr) и содержащие его липосомные композиции
CN117043159A (zh) Kras突变型癌症的治疗
CN121108109A (zh) 一种靶向alk蛋白的protac化合物及其抗肿瘤应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210621

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210721

R150 Certificate of patent or registration of utility model

Ref document number: 6918829

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250